팝업레이어 알림

팝업레이어 알림이 없습니다.

뇌질환의 혁신, 뉴로벤티(NeuroVenti)

INNOVATING TREATMENT
FOR BRAIN DEVELOPMENTAL DISORDERS

Development of patient-customized novel
drugs for optimal brain function utilization

DISCOVERING CANDIDATES FOR
OPTIMIZED BRAIN DISEASE TREATMENT

Provision of customized solutions
for intractable brain diseases

INTEGRATING PLATFORMS
OF TREATMENT
FOR BRAIN DISEASES

Holistic approach to brain well-being
from cradle to grave

NeuroVenti

세계 최초로 자폐증 치료제 후보물질(NV01-A02)의 FDA 희귀의약품 지정에 성공한 뉴로벤티(NeuroVenti)는
최근 특허청으로부터 자폐스펙트럼장애를 비롯한 정서장애 치료에 관한 신규 물질특허 등록을 통보 받아
현재 자폐스펙트럼장애 치료제의 국내 임상 2상 준비중으로, 중추신경계 장애에 대한 치료제 후보 발굴,
비임상 연구 컨설팅, 후보 물질의 비임상 효능 평가 및 안전성 평가를 위한 연구 서비스 등 비임상 CDRO도 제공하고 있습니다.

NeuroVenti is a global biotech startup
leading the development of neuroprotective
and therapeutic agents against neuronal disorders.

Read More

Pipeline

Introduce the pipeline of NeuroVenti

Development for Autism spectrum disorder

Autism Spectrum Disorder - NV01-A02

Development for Autism spectrum disorder

Autism Spectrum Disorder - NV01-A03

Development for Autism spectrum disorder

Autism Spectrum Disorder - NV01-O62

R&D Services

Introducing NeuroVenti's core research capabilities

- A variety of neurological disease models, in vivo and in vitro efficacy assessment system, and a system for mechanistic studies
- Establish the best research plan for your needs through the preclinical research consulting
- Select models, preliminary experiments, and establish evaluation methods through consultation after applying collaboration and research services
- Provide customer-oriented and optimized evaluation services

View More

News

Neuroventi signs a business agreement (MOU) w…

Neuroventi signs a business agreement (MOU) with Core Stem ChemOn23-09-05[Farm News = Reporter Seok-Hoon Lee] Neuroventi…
Neuroventi signs a business agreement (MOU) w…

Shin Chan-young, CEO of Neuroventi, “Challeng…

Shin Chan-young, CEO of Neuroventi, “Challenge in developing the first new drug for autism through drug re-creation”23-0…
Shin Chan-young, CEO of Neuroventi, “Challeng…

Neuroventi non-clinical CDRO service

One-stop solution for new drug development related to brain diseases![Neuroventi non-clinical CDRO service]- What is a n…
Neuroventi non-clinical CDRO service

Get rid of the poison in your mind and take g…

[Hankyoreh S] Shin Chan-young’s poison of the mind, medicine of the mind - too much is too much. - Alcohol, drinkin…
Get rid of the poison in your mind and take g…

Oxytocin receptor is not required for social …

Prairie voles are among a small group of mammals that display long-term social attachment between mating partners. Many…
이미지없음

Screening and services for autism among child…

In 2016, the prevalence of autism spectrum disorder in China among children aged 6–12 years was approximately 0·7% (an e…
이미지없음

Genomic architecture of autism from comprehen…

Fully understanding autism spectrum disorder (ASD) genetics requires whole-genome sequencing (WGS). We present the lates…
이미지없음

Analysis of difference in eye contact and bra…

Reluctance to make eye contact during natural interactions is a central diagnostic criterion for autism spectrum disorde…
이미지없음

Business area

Realizing Brain Wellness Society through Treatment of Neurodevelopmental Disorders
and Intractable Neurological Diseases, and Optimal Utilization of Brain Function

Drug
Development
CNS disorders’
therapeutic
candidates
research service
Platform
technology